Skip to main content
IMCR logo

IMCR · Immunocore Holdings plc

Track IMCR — free
$26.41 -0.22 (-0.83%) At close · Nov 20
Market Cap
$1.36B
Shares
51.68M
Volume · Nov 20 546.2K Avg daily vol (3M) 449.07K

Price & Indicators

 

Key stats

Close
$26.41
Fri 20 Nov
Open
$26.37
Fri 20 Nov
Average volume, 30 days
512K
shares a session
Short interest
7.8M
15.1% of shares · 14.2 days to cover
Day range
$25.61$26.82
Open $26.37 Close $26.41
52-week closing range
$26.41$40.22
Close $26.41 34.3% under the high
Short volume, last session
20%
Last earnings
Aug 6, 2026
Latest filing
10-Q · Nov 6
Price history
Feb 2021 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 13 wks
call held Feb 25, 2026

Latest documents

2026
Nov 17
Investor event
TAB-AM phase three data timing pushed to Q2 from year-end

Immunocore now expects TAB-AM phase three data in Q2, after previously saying as early as the end of the year. The company completed enrollment last quarter, which gave more insight into how events are accruing.

3 source passages
We were previously saying as early as the end of the year, really reflecting a couple of things. We completed an enrollment last quarter, and that gave us more specific insight into how those events were accruing from an independent stats group. So I think it's best to stick to Q2 at this point. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
KIMMTRAK revenue rises 9.9%; cash reaches $512.2 million

Immunocore Holdings plc generated $324.8 million in KIMMTRAK revenue for the nine months ended September 30, 2026, up 9.9%, while cash reached $512.2 million. Existing liquidity and anticipated KIMMTRAK revenue should fund operations for at least twelve months.

Revenue $102.22M ▼ 1.4% Net loss $14.22M Diluted EPS -$0.28
Read from the MD&A section
3 source passages
Revenue from sale of therapies, net | 324,826 | 295,538 | 29,288 | 9.9% For the nine months ended September 30, 2026, we generated revenue from sale of therapies, net of $324.8 million, due to the sale of KIMMTRAK, of which $204.6 million was in the United States, $103.5 million in Europe and $16.7 million in International. Revenue from sale of therapies, net increased in the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025, due to continued growth in the United States, Europe and international regions. We held cash and cash equivalents of $512.2 million and marketable securities of $389.1 million as of September 30, 2026. Based on our current operating plans, we expect that our existing cash and cash equivalents and marketable securities balances, along with anticipated revenue from KIMMTRAK, will enable us to fund our operating expenses and capital expenditure requirements for at least twelve months from the date of filing of this Quarterly Report. Open the document at this passage
Nov 6
Current report 8-K
KIMMTRAK sales reach $102.2 million; melanoma trial fully enrolled

Immunocore Holdings plc reported KIMMTRAK net revenues of $102.2 million in Q3 2026, while the Phase 3 TEBE-AM trial reached 540 patients; topline overall survival data are expected in the second quarter of 2027.

Financial results
3 source passages
KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. The registrational Phase 3 TEBE-AM trial, evaluating tebentafusp as monotherapy and in combination with pembrolizumab, versus a control arm in patients with previously treated advanced CM, has achieved its target enrollment of 540 patients. The trial is event-driven and topline overall survival data is expected in the second quarter of 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$429.30M
Trailing 12 months
Net income (TTM)
−$32.12M
Trailing 12 months
Revenue growth YoY
-1.4%
Year over year
Operating margin
-6.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$506.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.3%
Year over year · more shares
Price change (1Y)
-32.3%
Trailing year
Short interest
15.1%
Latest settlement · 14.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg −13%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −15%
trailing
6-month return −11%
trailing
YTD return −24%
this year
Relative strength −1%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $30 › 200d $31 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.08% of shares out · ▼ -0.1% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
131 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Strong
Revenue growth +43%
Y/Y
EPS growth +30%
Y/Y
Free cash flow $-15.1M
Balance sheet $74.6M
net cash
Quant / Vol
risk profile
High
Volatility 38%
annualized · 1-yr
Max drawdown −34%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 6, 2026
Sales-related rebate accruals · fourth quarter of 2026 $120M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
−13% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $30 › 200d $31 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.08% of shares out · ▼ -0.1% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
131 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $26 Now $26 · 0% Range high $40
vs 200-day avg -16% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
dose 1,200 as of the date of the release —
evaluable patients 17 As of June 2026 —
mDoR 24.1 As of June 2026 —
median duration of response (mDoR) 14.5 As of June 2026 —
median OS 20.3 As of June 2026 —
median progression-free survival (mPFS) 4.2 As of June 2026 —
mPFS 8.1 As of June 2026 —
overall response rate (ORR) 19% As of June 2026 —
partnered revenue $9.9M the three months ended September 30, 2026 filing —
patients still on study 10 As of June 2026 —
target enrollment 540 as of the date of the release —
two-year OS rate 70% As of June 2026 —
Control arm five-year overall survival rate 8% five years —
KIMMTRAK five-year overall survival rate 16% five years —
KIMMTRAK net product sales growth 16% the six months ended June 30, 2026 —
Mean duration of treatment 14 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMCR
Immunocore Holdings plc
this stock
$1.36B -23.9% +43.1% — 15.1%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
131
% held
99.2%
Net QoQ
-833.4K sh
Top holder
WELLINGTON MANAGEMENT GRO…
Held Float
View
Held by Funds
Fund positions
57
View
Short & Settlement
Short Interest Falling
Shares short
7.8M
Days to cover
14.2d
Change
-7.5K sh
View
Short Volume
Short vol %
20%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
219
Value
$6.1K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
49.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$400.0M
Net income (FY)
$-35.5M
EPS diluted
$-0.71
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
17

Immunocore now expects TAB-AM phase three data in Q2, after previously saying as early as the end of the year. The company completed enrollment last quarter, which gave more insight into how events are accruing.

View
Proposed Sales
Value
$385.3K
Shares
11.8K
Filed
Mar 11, 2026
View
Exempt Offerings
Offering
$140.0M
Filed
Jul 28, 2022
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Immunocore to present at upcoming…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
IMCR -11.8% -14.8% -10.7% -13.4% -23.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -3.2% -5.5% -1.5% -4.7% -25.1%
Key facts CIK 1671927 CUSIP 45258D105 13F (30d) 150 filings 122 filers Visit website Investor relations